Regencell Bioscience Holdings Limited (NASDAQ:RGC – Get Free Report)’s stock price traded up 0.3% during trading on Wednesday. The stock traded as high as $6.25 and last traded at $6.22. 56,125 shares changed hands during mid-day trading, a decline of 67% from the average daily volume of 172,676 shares. The stock had previously closed at $6.20.
Analyst Upgrades and Downgrades
A number of equities research analysts have commented on the company. Wall Street Zen downgraded Regencell Bioscience from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Regencell Bioscience in a research note on Monday, September 21st. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.
View Our Latest Stock Analysis on Regencell Bioscience
Regencell Bioscience Price Performance
Institutional Investors Weigh In On Regencell Bioscience
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Seven Fleet Capital Management LP purchased a new stake in shares of Regencell Bioscience in the 4th quarter worth about $92,000. Amundi purchased a new stake in shares of Regencell Bioscience in the first quarter valued at $219,000. Finally, Bank of America Corp DE increased its stake in shares of Regencell Bioscience by 59,113.8% during the 1st quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock valued at $437,000 after acquiring an additional 17,143 shares during the last quarter. 0.13% of the stock is currently owned by institutional investors and hedge funds.
Regencell Bioscience Company Profile
Regencell Bioscience Holdings Limited is a clinical-stage biotechnology company focused on developing traditional Chinese medicine (TCM) treatments for neurocognitive disorders and degenerative conditions. Its research has centered primarily on conditions such as dementia and attention-deficit/hyperactivity disorder (ADHD), with the goal of developing herbal formulations that may address underlying symptoms and disease-related challenges.
The company’s product development programs include proprietary TCM formulations intended for neurological and cognitive conditions.
Read More
- Five stocks we like better than Regencell Bioscience
- AST SpaceMobile’s BlueBird Progress Comes With Several Risks Still Unresolved
- Time to Nibble on MCD Stock After it Enters Oversold Territory?
- McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal Upside
- Corning and AT&T’s $3 Billion Fiber Deal Reveals Where AI Spending Goes Next
Receive News & Ratings for Regencell Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regencell Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
